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The 6-Hz corneal stimulation test is used to screen novel antiepileptic molecules to
overcome the problem of drug refractoriness. Although recognized as a standard test,
it has been evaluated only recently in the attempt to characterize the putative neuronal
networks involved in seizures caused by corneal stimulation. In particular, by recording
from the CA1 region we previously established that the hippocampus participates
to propagation of seizure activity. However, these findings were not corroborated by
using markers of neuronal activation such as FosB/∆FosB antigens. In view of this
discrepancy, we performed new experiments to characterize the changes in levels of
phosphorylated extracellular signal-regulated kinases1/2 (p-ERK1/2), which are also
used as markers of neuronal activation. To this aim, mice underwent corneal stimulation
up to three different times, in three sessions separated by an interval of 3 days.
To characterize a group in which seizures could be prevented by pharmacological
treatment, we also considered pretreatment with the ghrelin receptor antagonist
EP-80317 (330 µg/kg). Control mice were sham-treated. Video electrocorticographic
(ECoG) recordings were obtained from mice belonging to each group of treatment.
Animals were finally used to characterize the immunoreactivity for FosB/∆FosB and
p-ERK1/2 in the hippocampus. As previously shown, FosB/∆FosB levels were highly
increased throughout the hippocampus by the first induced seizure but, in spite of
the progressively increased seizure severity, they were restored to control levels after
the third stimulation. At variance, corneal stimulation caused a progressive increase in
p-ERK1/2 immunoreactivity all over the hippocampus, especially in CA1, peaking in the
third session. Predictably, EP-80317 administration reduced both duration and severity
of seizures, prevented the increase in FosB/∆FosB levels in the first session, and partially
counteracted the increase in p-ERK1/2 levels in the third session. The vast majority of
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p-ERK1/2 immunopositive cells were co-labeled with FosB/∆FosB antibodies,
suggesting the existence of a relationship between the investigated markers in
a subpopulation of neurons activated by seizures. These findings suggest that
p-ERK1/2 are useful markers to define the aggravation of seizures and the response
to anticonvulsant treatments. In particular, p-ERK1/2 expression clearly identified the
involvement of hippocampal regions during seizure aggravation in the 6-Hz model.
Keywords: 6-Hz corneal stimulation, electrocorticography, epilepsy, EP-80317, extracellular signal-regulated
kinase (ERK), FosB, hippocampus, growth hormone secretagogues
INTRODUCTION
In the early 1950s, the 6-Hz corneal stimulation model of
‘‘psychomotor seizures’’ was proposed as a tool to screen new
anticonvulsants (Brown et al., 1953; White et al., 2002). More
recently, it has been identified as a model for antiepileptic
drug (AED)-resistant partial seizures (Barton et al., 2001;
White et al., 2006). The reason for this was the unique result
that led to identify the anticonvulsant effect of the clinically
effective AED levetiracetam (Barton et al., 2001). Indeed, the
6-Hz corneal stimulation model has been included in the
anticonvulsant screening project established by the National
Institutes of Neurological Disorders and Stroke (Smith et al.,
2007). Additionally, this model has been adopted to propose a
new kindling protocol, also aimed at identifying new effective
AEDs (Walrave et al., 2015). Despite the large use of 6-Hz
corneal stimulation to induce convulsions, the cerebral regions
participating to seizures induced in this model are still largely
undetermined. Moreover, it is not established if this model may
mimic at least some pathophysiological features of the most
diffused type of refractory epilepsy, i.e., temporal lobe epilepsy
(TLE; Curia et al., 2014). For instance, a prominent feature of
TLE models is the presence of a process named ‘‘secondary
epileptogenesis’’ (Williams et al., 2009; Pitkänen and Lukasiuk,
2011; Löscher et al., 2015; Van Nieuwenhuyse et al., 2015), by
which a progressive aggravation of seizures occurs in epileptic
animals.
Very few investigations attempted to define the neuronal
networks involved in seizures induced by 6-Hz corneal
stimulation (Barton et al., 2001; Duncan and Kohn, 2005;
Giordano et al., 2015). By using c-Fos immunolocalization,
different brain regions including the piriform cortex, cingulate
and perirhinal cortices, neocortex and amygdala were found
to present increased c-Fos levels immediately after seizure
induction (Barton et al., 2001). Partially confirming these
data, an autoradiographic analysis of 14C-2-deoxyglucose uptake
revealed that neuronal cell populations were acutely involved
by seizures in the neocortex, lateral amygdala and caudate-
putamen (Duncan and Kohn, 2005). However, these experiments
took into consideration only the responses to acute seizures,
whereas the possibility that the identified cerebral regions
could be involved in more durable phenomena, such as
those characterizing secondary epileptogenesis (Pitkänen and
Lukasiuk, 2011; Löscher et al., 2015), was never assessed.
To this aim, we developed a model of repeated 6-Hz
corneal stimulation in which an epileptogenic phenomenon,
consisting of seizure worsening concomitant with progressive
recruitment of the hippocampus, occurred (Giordano et al.,
2015).
Although we previously demonstrated by
electrocorticographic (ECoG) recordings that the CA1 region
of the hippocampus was involved in seizure propagation when
exposed to repeated 6-Hz corneal stimulation, this finding
was not accompanied by durable changes in the expression of
neuronal activity markers in the same region (Giordano et al.,
2015). In particular, we evaluated the expression of FosB/∆FosB
antigens, which are known to be markedly induced either in
seizure models (Chen et al., 1995; Mohapel et al., 2001), or in
models of epilepsy (Morris et al., 2000; Biagini et al., 2005; Curia
et al., 2013). Additionally, FosB/∆FosB isoforms were directly
involved in epileptogenesis since their deletion was associated
with adult-onset spontaneous epilepsy (Yutsudo et al., 2013).
Inconsistently, in our experiments we found that FosB/∆FosB
levels were initially elevated in the hippocampus, in response
to the first corneally induced seizure, but then they went back
to control levels by repeating the seizure induction. Moreover,
the results obtained with FosB/∆FosB were at odds with those
observed by recording in CA1 of the same animals, in which we
demonstrated the appearance of epileptic activity in association
with aggravation of seizures (Giordano et al., 2015).
In order to further evaluate the involvement of hippocampal
regions in mice stimulated by 6-Hz corneal electroshocks,
we decided to characterize the expression of phosphorylated
extracellular signal-regulated kinases 1/2 (p-ERK1/2) in response
to repeated seizure induction. These markers have been found
to be widely expressed in the hippocampus of animals exposed
to seizures induced by kainate (Kim et al., 1994; Crespo-Biel
et al., 2007), pilocarpine (Garrido et al., 1998; Berkeley et al.,
2002; Houser et al., 2008), bicuculline (Gass et al., 1993; Ben
et al., 2014), and dopamine D1 receptor agonists (Bozzi et al.,
2011; Gangarossa et al., 2011, 2014; Bozzi and Borrelli, 2013).
We also found p-ERK1/2 to be induced by audiogenic seizures
in mice affected by fragile X syndrome (Curia et al., 2013)
and, interestingly, changes in p-ERK1/2 have been associated
to a different sensitivity to proconvulsant stimuli (Glazova
et al., 2015). In order to characterize p-ERK1/2 expression
in the repeated 6-Hz corneal stimulation model, we designed
an experiment in which p-ERK1/2 was characterized in the
hippocampus of mice exposed to one or three sequential
seizures. Additionally, we considered the possibility to
antagonize seizures by administering the anticonvulsant
EP-80317 (Biagini et al., 2011), so to determine the modulation
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of neuronal activity markers to this pharmacological challenge.
Overall, we identified p-ERK1/2 as a critical mediator involved
in the hippocampal response to 6-Hz corneally induced
seizures.
MATERIALS AND METHODS
Animals and Treatments
Four-week-old male CD-1 mice (n = 44; Charles River,
Calco, Italy) were used for this study. Six of these animals
(control group) were used to determine basal levels of the
investigated markers and were not treated or stimulated,
but they were handled and exposed to the same procedure
as the others. Nineteen were intraperitoneally (i.p.) saline-
treated mice, and other 19 mice received i.p. injections
of the ghrelin receptor antagonist EP-80317 (Haic-D-Mrp-
D-Lys-Trp-D-Phe-Lys-NH2, produced by conventional solid
phase synthesis; 330 µg/kg), previously shown to be an
anticonvulsant (Biagini et al., 2011). Injections of EP-80317
or saline were performed 15 min before each session of
corneal stimulation. All experiments were approved by the
Italian Ministry of Health (Ministero della Salute) (92/2013)
and performed in accordance with the European Directive
2010/63/EU.
Corneal Stimulation Protocol
Mice were stimulated once and let to recover for 3 days before
being stimulated again. Corneal stimulation was performed as
previously described (Giordano et al., 2015). Briefly, a topical
eye anesthetic (0.4% oxybuprocaine hydrochloride eye drops,
Novesin, Novartis, Switzerland) was applied 10 min before
stimulation. Stimulation (fixed current intensity of 32 mA,
pulse width of 0.2 ms, duration of 3 s, frequency of 6 Hz)
was delivered via corneal electrodes connected to a stimulator
(ECT Unit 5780; Ugo Basile, Comerio, Italy). Seizure severity
was ranked according to the following scores: 1, stunned
posture and eye blinking; 2, head nodding, Straub tail and
repetitive rhythmic movements (stereotypies) such as chewing;
3, unilateral or alternating forelimb clonus; 4, generalized tonic-
clonic convulsions without loss of posture, or rearings; and
5, generalized tonic-clonic convulsions with loss of posture.
Seizures were first scored immediately after corneal stimulation
by direct observation, then reanalyzed on video recordings to
quantify the duration of behavioral changes by an investigator
unaware of the stimulation session. Recovery from seizures
was defined by the reappearance of a normal exploratory
behavior.
Electrodes Implantation for
Electrocorticographic (ECoG) Recordings
Few mice (n = 3, respectively, for mice treated with saline
or EP-80317) were implanted to perform ECoG recording
of the induced seizures. For electrode implantation, mice
were anesthetized with ketamine (150 µg/g, i.p.) + xylazine
(10 µg/g, i.p.). Guiding holes were drilled and epidural
electrodes (stainless steel Ø = 1 mm; PlasticsOne, Roanoke,
VA, USA) were implanted in frontal (Bregma 0 mm,
3 mm lateral from midline) and occipital cortices (Bregma
−3.5 mm, 3 mm lateral from midline) of right hemisphere
(Giordano et al., 2015). One electrode was implanted below
lambda on the midline and used as reference. Electrodes
were connected by steel wire to terminal gold pins (Bilaney
Consultant GmbH, Düsseldorf, Germany) that were inserted
in a plastic pedestal (PlasticsOne, Roanoke, VA, USA)
cemented on the mouse head. At the end of the surgery,
a gel containing 2.5 g lidocaine chloride, 0.5 g neomycin
sulfate and 0.025 g fluocinolone acetonide (Neuflan gel;
Molteni Farmaceutici, Scandicci FI, Italy) was applied to avoid
sufferance and risk of infection. These mice were not used for
immunohistochemistry to avoid any possible interference with
expression of the investigated markers of stress cause by the
implant.
Video ECoG Recordings
Mice were placed in cages without cover to allow cable
connection between headset and preamplifiers. Electrical
brain activity was digitally filtered (0.3 Hz high-pass, 500 Hz
low-pass), acquired at 1 kHz per channel, and stored on
personal computer as the mathematical subtraction of traces of
recording electrodes minus traces of reference electrode (only
for epidural electrodes), using a PowerLab8/30 amplifier
connected to 4 BioAmp preamplifiers (ADInstruments;
Dunedin, Otago, New Zealand). Videos were digitally
captured by a camera connected to the computer, which
was synchronized to the EcoG traces by LabChart 7 Pro internal
trigger.
Immunohistochemistry
Mice (n = 6 controls; n = 16 for each treatment group)
were deeply anesthetized with isoflurane (∼10 s), 14–17 h
after the seizure test. They were perfused transcardially with
phosphate buffered saline (PBS, pH 7.4), followed by Zamboni’s
fixative (pH 6.9). Brains were isolated and postfixed at
4◦C in the same fixative for 24 h and then transferred
into 15% and 30% sucrose solution (Vinet et al., 2016).
Horizontal sections of 50 µm were cut using a freezing
sliding microtome (Leica SM2000 R; Leica, Nussloch, Germany).
Sections were washed in PBS, treated with 3% H2O2 in
PBS (20 min) in order to quench endogenous peroxidase
activity and washed again in PBS. Then, they were blocked
1 h in PBS/0.1% Triton X-100 containing 5% normal goat
serum and incubated at 4◦C with a rabbit polyclonal anti-
FosB/∆FosB (H-75, sc-7203, Santa Cruz Biotechnology, Santa
Cruz, CA, USA; 1:250, overnight) and a mouse monoclonal anti-
p-ERK1/2 (Thr202/Tyr204, cat-9106, Cell Signal Technology,
Beverly, MA, USA; dilution 1:10,000, 48 h). After washing,
sections were incubated for 1 h firstly with a biotinylated
anti-rabbit or, respectively, anti-mouse secondary antibody
(Vector Laboratories, Burlingame, CA, USA; 1:200) and
secondly with the avidin-biotin-peroxidase complex (Elite
ABC Kit; Vector Laboratories, Burlingame, CA, USA). The
immunostaining was developed in 0.05% 3,3-diaminobenzidine
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tetrahydrochloride for 5 min (Sigma-Aldrich, Milan, Italy) by
adding 0.03% H2O2.
Image Analysis
Immunostained sections mounted on gelatin-coated slides
and relative to bregma from −8.04 mm to −5.04 mm for
hippocampal CA1, CA3, and dentate gyrus (DG) regions were
analyzed using an Axioskop microscope (Carl Zeiss Vision
GmbH, Munchen, Germany) equipped with a 10× objective.
For each area of interest, images were digitally captured by
a Sony CCD-IRIS B–W video camera, along the ventrodorsal
direction of the brain (approximately 6–7 serial horizontal
sections separated by 0.5 mm). A mouse brain atlas-C57BL/6J
horizontal1 was used to assess brain sections. The number
of immunoreactive cells per mm2 was quantified using the
image analysis software KS300 (Carl Zeiss Vision GmbH), as
previously detailed (Biagini et al., 2005; Curia et al., 2013;
Giordano et al., 2015). The border of all analyzed regions
was manually traced and the sampled areas, expressed in
mm2, were automatically determined. Background values in
each section were acquired from areas that did not contain
any stained cell, such as the angular bundle. FosB/∆FosB
immunopositive cells were determined in each area as the
number of immunopositive profiles after transformation in
D-circles (i.e., the diameter of circles having the same area as
measured) by considering a minimum cut-off value of 7 µm;
p-ERK1/2 immunopositive cells were instead manually counted.
Cell count was then normalized by the sampled area and
expressed as cellular density (n/mm2). All measurements were
taken bilaterally and the final values represent the left-right
average.
Double Immunofluorescence
Sections were washed thrice in PBS at room temperature and
permeabilized for 1 h in PBS/0.1% Triton X-100 containing 5%
normal goat serum. For double immunolabeling, sections were
incubated overnight with rabbit polyclonal anti-FosB/∆FosB
(1:250) and mouse monoclonal anti-p-ERK1/2 (1:500)
antibodies. After washing, sections were incubated for 3 h
at room temperature with secondary antibodies Alexa Fluor
488-labeled goat anti-rabbit (A-11001; Invitrogen, Carlsbad,
CA, USA; 1:500) and Alexa Fluor 594-labeled goat anti-mouse
antibody (A-11005; Invitrogen, Carlsbad, CA, USA; 1:500).
Sections were mounted and coverslipped with Mowiol. Images
were acquired using a Leica TCS SP2 (Leica Laser technik,
Heidelberg, Germany) confocal multiband scanning laser
equipment with AOBS system adapted to an inverted Leica
DM IRE2 microscope interfaced with an Argon-Kripton
laser set at a power of 8 mW in each line (488, 568) and
operating in the single scan acquisition mode. To minimize
the noise and to keep a low photobleaching rate, we selected
an acquisition time of 2 s per scan and averaged two scans
to produce each 1024 × 1024 pixel image. All images of
fluorescent neurons in CA1 were taken at HCX PL APO
40× magnification and the final images were the merge of
1http://www.mbl.org/atlas232/atlas232_frame.html
a rostro-caudal series of 4–6 images in a depth of 4–6 µm.
The number of double-labeled cells were counted using Fiji
software2.
Statistics
Seizure duration was analyzed using one-way analysis of variance
(ANOVA) and the post hoc Fisher’s least significant difference
(LSD) test. FosB/∆FosB and p-ERK1/2 data were compared
by using the same statistical approach. The Fisher’s exact test
was used to compare scores of motor responses, classified as
convulsions with or without loss of posture, in the various
groups of treatment. All statistical analyses were performed using
Sigmaplot 11 (Systat Software, San Jose, CA, USA). When not
otherwise indicated, results are shown as mean ± standard
error of the mean and P < 0.05 was considered statistically
significant.
RESULTS
Seizures Induced by Repeated 6-Hz
Corneal Stimulation Were Attenuated by
Treatment With EP-80317
We analyzed severity and duration of seizures induced by
6-Hz corneal stimulation (Figure 1). Increased severity was
determined as the development of generalized tonic-clonic
convulsions with loss of posture, whereas seizure termination
was established as the reappearance of a normal exploratory
behavior. Consistent with previous findings (Giordano et al.,
2015), the percentage of mice which displayed generalized tonic-
clonic seizures associated with loss of posture significantly
increased (P < 0.05, session 3 vs. session 1; Fisher’s exact
test) in mice treated with saline (Figure 1A). Interestingly, only
a limited number of mice treated with EP-80317 developed
generalized tonic-clonic convulsions, being significantly different
from saline-treated mice (P < 0.05, in both session 2 and
session 3). Thus, by limiting generalized tonic-clonic seizures
EP-80317 produced anticonvulsant effects which did not subside
in the course of three different sessions of corneal stimulation.
The overall seizure duration was shorter in mice treated
with EP-80317 compared to saline-treated mice (P < 0.05,
Fisher’s LSD test) during the first session of seizure induction
(Figure 1B). However, as mice more quickly recovered from
seizures after the first induction (Giordano et al., 2015), the
difference in the overall seizure duration was no more evident
in the second and third session of corneal stimulation. Especially
in the third session, the reduction in seizure duration was
significant in both groups of treatment compared with the
respective seizure duration of the first session (P < 0.01 for both
groups, session 3 vs. session 1).
By further analyzing 6-Hz corneally induced seizures to
distinguish motor (convulsions) from non-motor (stunned
posture; see Giordano et al., 2015) components, we could explain
the reason for the decreased seizure duration, which was due to
reduction in the immobility period that followed convulsions.
2http://fiji.sc/Fiji
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FIGURE 1 | Behavioral response to repeated 6-Hz corneal stimulation in mice treated with saline or EP-80317. Seizures were evaluated for severity and
duration. Severity was measured as the percentage of mice developing generalized tonic-clonic seizures associated with loss of posture (A). Note that loss of
posture occurred in a progressively higher percentage of saline-treated mice (#P < 0.05 vs. session 1 in the same treatment group, Fisher’s exact test; ∗P < 0.05 vs.
saline-treated mice in sessions 2 and 3). The seizure duration (B–D) was evaluated separately for convulsions (C, motor component) and stunned posture
(D, non-motor component), or as overall duration (B, including both components). Note that the overall duration decreased progressively after each session in both
groups (##P < 0.01, session 3 vs. 1; Fisher’s least significant difference (LSD) test). Interestingly, a significantly lower overall duration was initially found in mice treated
with EP-80317 (∗P < 0.05 vs. saline-treated mice in session 1; Fisher’s LSD test). When considering only the motor component (C), this was reduced by EP-80317
in the first two sessions (∗P < 0.05). Concerning the non-motor component (D), a significant decrease was found in saline-treated mice (##P < 0.01, session 2 and
3 vs. session 1). In mice treated with EP-80317 group, the non-motor component did not change in the various sessions and it was initially shorter than in
saline-treated mice (∗∗P < 0.01, session 1).
Precisely, the seizure motor component did not change its
duration in saline-treated mice across the three different sessions
of stimulation (Figure 1C), whereas the non-motor component
was significantly shortened both in the second and third session
of seizure induction (P < 0.01, session 2 and 3 vs. session 1
in saline-treated mice; Fisher’s LSD test; Figure 1D). The
non-motor component was also significantly shorter in EP-80317
compared to saline-treated mice in the course of the first session
of seizure induction (P< 0.01), but this difference was not found
in the following sessions of corneal stimulation (Figure 1D).
Notably, EP-80317 significantly shortened the motor component
with respect to saline-treated mice in both the first and second
session of corneal stimulation (P < 0.05, Fisher’s LSD test).
However, in the third session both groups presented similar
values, suggesting that a certain degree of resistance to the
anticonvulsant effects of EP-80317 was developed by repeating
the seizure induction.
In few mice we also performed ECoG recordings to compare
the observed response with our previous results (Giordano et al.,
2015). In these animals we confirmed that the electrographic
seizure corresponded to the visually scored motor component
quantified in Figure 1C, and that the non-motor component was
represented by flattening of the electrographic signal, as indicated
in Figure 2. However, the very low number of animals (n = 3 for
each group) used for ECoG recordings did not allow any reliable
quantitative analysis of the seizure characteristics.
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FIGURE 2 | Electrocorticographic (ECoG) activity during seizures induced by 6-Hz corneal stimulation. EcoG traces obtained from frontal cortex of one
out of three representative mice. Note that the trace clearly shows two components: (i) the ictal event corresponding to the motor component of the seizure; and
(ii) the post-ictal event, characterized by flattening of basal activity corresponding to the non-motor component of seizures. Traces were respectively taken from a
saline-treated mice (A) or an animal treated with EP-80317 (B). No quantification is provided because of the low number of animals per group (n = 3). RFC, right
frontal cortex.
EP-80317 Prevented the Increase in
FosB/∆FosB Expression Initially Observed
in the Hippocampus of Saline-Treated Mice
We re-evaluated the effects of repeated exposure to 6-Hz
corneal stimulation on FosB/∆FosB immunoreactivity in the
hippocampal regions CA1, CA3, and DG (see Giordano et al.,
2015). In these experiments, we quantified the changes occurring
after the first and third session of seizure induction. FosB/∆FosB
immunoreactivity was barely detectable in unstimulated control
mice (Figure 3A). In all hippocampal regions of saline-
treated mice, a prominent increase in FosB/∆FosB levels was
observed after the first 6-Hz corneal stimulation, reaching
a statistically significant level in all the considered regions
(Figures 3B–D). Interestingly, FosB/∆FosB immunoreactivity
was also significantly higher (P < 0.001, Fisher’s LSD test) in
saline-treated mice compared to animals treated with EP-80317.
On the other hand, treatment with EP-80317 prevented
any increase in FosB/∆FosB levels in the first session of
corneal stimulation, in all hippocampal regions. Consistent
with previous observations (Giordano et al., 2015), after the
third seizure induction FosB/∆FosB immunoreactivity returned
to basal levels in saline-treated mice in all hippocampal
regions. Again, no change was noticed in mice treated with
EP-80317.
Levels of p-ERK1/2 Immunoreactivity
Progressively Increased in the
Hippocampus of Mice Exposed to
Repeated 6-Hz Corneal Stimulation
As found for FosB/∆FosB, neurons immunopositive
to p-ERK1/2 antibodies were scanty in basal condition
(Figure 4A). After the first session of seizure induction,
p-ERK1/2 immunoreactivity increased significantly in
the CA1 hippocampal region of EP-80317 and saline-
treated mice (P < 0.05 for both groups, Fisher’s LSD test).
Notably, after the third session of seizure induction levels of
p-ERK1/2 immunoreactivity were markedly elevated in all the
analyzed hippocampal regions, with the highest values found in
CA1 (Figures 4B–D). EP-80317 administration did not prevent
the increase in p-ERK1/2 immunoreactivity observed in the
various hippocampal regions, but this change was significantly
attenuated (P < 0.001 for all hippocampal regions) when
comparing these mice with those receiving the saline injection
(Figures 4B–D).
Neurons Immunopositive to p-ERK1/2 Also
Expressed FosB/∆FosB
In order to determine whether p-ERK1/2 and FosB/∆FosB were
expressed in distinct cells or coexpressed in the same neurons,
we performed a double-immunofluorescence experiment. Cells
expressing all the investigated markers (Figure 5) were counted
and expressed as percentages of p-ERK1/2 immunopositive
neurons. In control animals, an average of 70% ± 23%
of p-ERK1/2 immunopositive neurons were also labeled by
FosB/∆FosB antibodies. In treatment groups evaluated after
the first session of seizure induction, double-labeled neurons
were, respectively, 79% ± 15% in saline-treated mice, and
77% ± 7% in mice treated with EP-80317. After the third
seizure induction, double-immunolabeled neurons did not
change and were, respectively, 82% ± 4% in saline-treated
mice, and 77% ± 7% in mice treated with EP-80317. As no
significant differences were found, the increasing number of
p-ERK1/2 immunopositive neurons (Figure 4) and, conversely,
the reduced immunoreactivity for FosB/∆FosB (Figure 3),
did not affect the overall coexpression of the investigated
markers.
DISCUSSION
We have further explored the repeated 6-Hz corneal stimulation
model to characterize a possible marker of the progressive
involvement of the hippocampus in seizure worsening, as
well as to test the effects of treatment with an anticonvulsant
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FIGURE 3 | FosB/∆FosB immunoreactivity in hippocampal regions of mice treated with saline or EP-80317 and exposed to different sessions of 6-Hz
corneal stimulation. In (A), FosB/∆FosB immunoreactivity is illustrated in CA1, CA3, and dentate gyrus (DG), in a representative unstimulated control (ctrl) mouse.
Besides, FosB/∆FosB immunoreactivity is also shown in mice exposed to one or three different sessions of 6-Hz corneal stimulation, and pretreated with saline (sal)
or EP-80317 (ep). Immunoreactivity was measured and results are illustrated in (B–D). Note that FosB/∆FosB levels were significantly increased in CA1 (B), CA3
(C), and DG (D) after the first session, in saline-treated mice only (◦◦P < 0.01, ◦◦◦P < 0.001 vs. controls; Fisher’s least significant difference test). In
EP-80317-treated mice, FosB/∆FosB levels were instead maintained at basal values and were significantly different from saline-treated mice (∗∗∗P < 0.001 vs. sal-1).
Note also that FosB/∆FosB levels were significantly reduced in the third session of saline-treated mice (##P < 0.01, ###P < 0.001 vs. sal-1). Scale bar, 50 µm.
on recurrent seizures and the respective markers of neuronal
activation. As major findings of our investigation we determined
that: (i) p-ERK1/2 immunoreactivity was progressively
induced, especially in CA1, by repeating seizure induction;
and (ii) this phenomenon was attenuated by administration
of the anticonvulsant EP-80317. Additionally, we confirmed
that FosB/∆FosB immunoreactivity was initially increased, but
then it normalized in the course of further seizure induction.
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FIGURE 4 | Changes in phosphorylated extracellular signal-regulated kinases 1/2 (p-ERK1/2) immunoreactivity in hippocampal regions of mice
treated with EP-80317 and exposed to different sessions of 6-Hz corneal stimulation. In (A), p-ERK1/2 immunoreactivity is illustrated in CA1, CA3, and DG,
in a representative unstimulated control (ctrl) mouse. Moreover, p-ERK1/2 immunoreactivity is also shown in mice exposed to one or three different sessions of 6-Hz
corneal stimulation and pretreated with saline (sal) or EP-80317 (ep). Immunoreactivity was measured and results are illustrated in (B–D). Note that
p-ERK1/2 expression was initially increased in CA1 (◦P < 0.05 vs. controls; Fisher’s least significant difference test), both in EP-80317 and saline-treated mice. After
the third seizure, immunopositive cells increased also in CA3 (C) and DG (D) (◦◦P < 0.01, ◦◦◦P < 0.001 vs. controls) and were higher than in the initial session
(#P < 0.05, ##P < 0.01, ###P < 0.001 vs. session 1 of the respectively considered group of treatment). However, the changes observed in mice treated with
EP-80317 were less pronounced than in saline-treated mice (∗∗∗P < 0.001 vs. sal-3). Scale bar, 50 µm.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 December 2016 | Volume 10 | Article 281
Giordano et al. p-ERK1/2 and Seizure Aggravation
FIGURE 5 | Double immunofluorescence confocal laser scanning
micrographs of mice exposed to repeated 6-Hz corneal stimulation.
Photomicrographs illustrating co-labeling with phosphorylated extracellular
signal-regulated kinases 1/2 (p-ERK1/2) (green) and FosB/∆FosB (red) in
CA1 of representative mouse for each group of treatment. Double-label
immunofluorescence revealed the coexpression of p-ERK1/2 and
FosB/∆FosB in the experimental groups. Scale bar, 75 µm.
This occurred in spite of the consistent seizure aggravation,
already noticed in our previous investigation (Giordano et al.,
2015).
In our previous experiments, we used an antibody against
FosB/∆FosB chosen on the basis of the transient induction of
immunoreactivity observed after exposure to status epilepticus
(Biagini et al., 2005), as well as for the subsequent reappearance
of immunoreactivity for FosB/∆FosB in epileptic rats (Biagini
et al., 2008). Notably, this antibody appeared to be useful
in describing the modifications in neuronal network activity
even in the presence of different types of seizures (Chen
et al., 1995; Curia et al., 2013). However, the ability of
this antibody to react with both FosB and ∆FosB precluded
the possibility to correctly identify the isoform recognized
in our animals. Indeed, the changes observed in corneally
stimulated mice were transient, so that the FosB/∆FosB antibody
probably identified the FosB isoform, whose induction is
generally followed by the return to basal levels, rather than
the ∆FosB variant, which instead accumulates in response to
repeated stimulations (Nestler, 2015). Moreover, the finding
of increased FosB/∆FosB immunopositivity after the initial
induction, followed by lack of changes in the last seizure,
suggests that a desensitization occurred in mice exposed to
repeated 6-Hz corneal stimulation. Indeed, this phenomenon
of desensitization has been shown for different members of
the Fos family in various conditions and also in response
to pharmacological treatments, with the notable exception of
∆FosB (Ivkovic et al., 1994; Nakahara et al., 1999; Perrotti et al.,
2004; see Nestler, 2015). Precisely, we interpreted the induction
of FosB/∆FosB immunopositivity as due to a novelty effect
followed by adaptation, as found also in a different model (Harris
et al., 2007).
To address the problem of desensitization encountered
with the FosB/∆FosB antibody, we investigated the pattern
of p-ERK1/2 expression in the same condition used for the
previous markers (Giordano et al., 2015). Quantification of
neurons expressing p-ERK1/2 immunoreactivity revealed a
remarkable increase in this marker levels, especially in the
CA1 hippocampal region. This region was previously found
to present seizure activity only when exposed to repeated
6-Hz corneal stimulations, suggesting the occurrence of an
epileptogenic process within the hippocampus (Giordano
et al., 2015). It is noteworthy that, in the pilocarpine
model of TLE, hippocampal p-ERK1/2 immunoreactivity
increased only at the end of the epileptogenic process
(Houser et al., 2008). Although the pilocarpine model
(Curia et al., 2008) is very different from the repeated
6-Hz corneal stimulation test, it is suggestive that in both
conditions there was a coincidence between the increase
in p-ERK1/2 immunoreactivity and the appearance of an
epileptogenic process. In agreement with this interpretation,
it has been reported that phosphorylation of ERK1/2 is
stimulated by increased glutamate levels, such as those found
in the course of seizures (Jeon et al., 2000; Otani et al.,
2003). Moreover, reduction of ERK1/2 phosphorylation was
correlated with in vitro decreased ictogenesis (Merlo et al., 2004),
definitely suggesting a role for p-ERK1/2 in promoting seizures.
Consistently, increased p-ERK1/2 levels were shown to be
associated with spontaneous epileptic seizures in mice expressing
a constitutively active form of MEK1, which activates ERK1/2
(Nateri et al., 2007).
Although the different markers investigated in our
experiments followed an opposite trend, we found that the vast
majority of neurons expressing p-ERK1/2 were immunopositive
for FosB/∆FosB. A coexpression of these markers was previously
demonstrated in about half of neurons immunopositive
for p-ERK1/2, in a model of genetic epilepsy (Curia et al.,
2013). In normal animals, p-ERK1/2 and FosB/∆FosB can be
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both induced by physiological stimuli (Kuroda et al., 2007;
Perrotti et al., 2013). Similarly, p-ERK1/2 and FosB/∆FosB
were also upregulated in a model of Parkinson’s disease
(Doo et al., 2014). Indeed, lines of evidence support the
possibility that p-ERK1/2 can directly regulate FosB levels
(Kuroda et al., 2007). Thus, it can be hypothesized that the
coexpression of p-ERK1/2 and FosB/∆FosB occurred in a
subpopulation of FosB/∆FosB immunopositive cells, in which
p-ERK1/2 directly stimulated gene expression for FosB. The
remaining FosB/∆FosB immunopositive cells, which did
not express p-ERK1/2, were probably activated by different
stimuli. We previously hypothesized that the first induction of
FosB/∆FosB immunoreactivity could be due to the stressful
procedure required to cause the seizure. Subsequently, animals
may become accustomed to the corneal stimulation procedure,
so that the effects of stress on FosB/∆FosB immunoreactivity
may subside (Giordano et al., 2015). In this case, neurons
expressing both markers could represent a population
specifically responsive to seizures, so to be a possible therapeutic
target to prevent the epileptogenic changes observed in our
model.
The results obtained by treating mice with EP-80317
appear to support this hypothesis. EP-80317 is a ghrelin
receptor antagonist and CD36 ligand (Davenport et al., 2005;
Callaghan and Furness, 2014) previously found to efficiently
counteract seizure induction in rats treated with pilocarpine
(Biagini et al., 2011). Here we show for the first time
that this anticonvulsant is also able to antagonize seizures
induced by 6-Hz corneal stimulation. Especially, EP-80317
was able to prevent the increase in seizure severity, but only
temporarily decreased the seizure duration. In both cases,
the anticonvulsant effect was associated with attenuation of
changes in p-ERK1/2 immunopositivity in the hippocampus,
an effect that was more evident in the third session of seizure
induction when the increase in p-ERK1/2 immunoreactivity
was more significant. This observation confirms that the
hippocampus is involved in seizure worsening in the 6-Hz
corneal stimulation model. Additionally, the transient effect
of EP-80317 on the overall seizure duration suggests the
appearance of refractoriness to the tested anticonvulsant.
Indeed, the relation with pharmacoresistance is a recognized
feature of the 6-Hz corneal stimulation model (Barton et al.,
2001; White et al., 2002), and it could be of interest to
assess whether the expression of p-ERK1/2 immunoreactivity
is associated with refractoriness to AEDs. Definitely, these
overall features, including seizure aggravation, refractoriness to
anticonvulsants, and the progressive hippocampal involvement,
could be part of a process otherwise defined as ‘‘secondary
epileptogenesis’’ (Pitkänen and Lukasiuk, 2011; Löscher et al.,
2015), which is only partially characterized and that requires
the availability of reproducible animal models to be properly
addressed.
In conclusion, we provide evidence that some critical
processes, such as epileptogenesis and refractoriness to
AEDs, could be reproduced especially in the hippocampus
exposed to repeated 6-Hz corneal stimulation. Our findings
also suggest that ERK1/2 phosphorylation may be involved
in both these processes, since levels of p-ERK1/2 increased
more dramatically after the third session of corneal
stimulation, which was previously demonstrated to precede
the appearance of hippocampal seizures (Giordano et al., 2015).
Concomitantly, the increase in p-ERK1/2 levels anticipated
the reduction in EP-80317 efficacy, suggesting that prevention
of ERK1/2 phosphorylation and of the related downstream
signals could represent possible novel targets for development of
alternative AEDs.
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